The percentage of CD45+ cells and the expression of PD-1 on CD45+ cells in B7-H1-positive and B7-H1-negative tumor regions
| Tumor specimen | Age (yrs) | Sex | Histology (differentiation) | CD45+ cells* | PD-1+/CD45+ cells† | ||||
|---|---|---|---|---|---|---|---|---|---|
| B7-H1-positive region | B7-H1-negative region | B7-H1-positive region | B7-H1-negative region | ||||||
| 1 | 73 | F | Ad(W) | 23.4 | 43.3 | 11 | 28 | ||
| 2 | 53 | F | Ad(M) | 32.2 | 52.9 | 7.2 | 9.8 | ||
| 3 | 60 | M | Ad(M) | 11.2 | 42.8 | 2.2 | 16 | ||
| 4 | 79 | F | Sq(W) | 38.2 | 42.9 | 12 | 15 | ||
| 5 | 57 | M | Ad(W) | 8.1 | 75.5 | 2.8 | 31 | ||
| Mean ± SD | 22.6 ± 13 | 51.5 ± 14.1 | 7.1 ± 4.5 | 20.2 ± 9.0 | |||||
| P = 0.01‡ | P = 0.02‡ | ||||||||
Abbreviations: Ad, adenocarcinoma; Sq, squamous cell carcinoma; W, well differentiated; M, moderately differentiated.
* Percentage of CD45+ cells per 1000 total nuclei counted within a B7-H1-positive tumor region/B7-H1 tumor-negative region.
† Percentage of PD-1+ cells per CD45+ cells counted within a B7-H1-positive tumor region/B7-H1-negative tumor region.
‡ Wilcoxon’s rank-sum test (B7-H1-positive tumor region versus B7-H1-negative tumor region).